Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes

Chirality

Volumn 17, Issue 6, 2005, Pages 338-344

  Miura, Masatomo ^a   Tada, Hitoshi ^a   Yasui Furukori, Norio ^b   Uno, Tsukasa ^c   Sugawara, Kazunobu ^c   Tateishi, Tomonori ^b   Suzuki, Toshio ^a  

^a AKITA UNIVERSITY HOSPITAL   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c HIROSAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Clarithromycin; CYP2C19; CYP3A4; Enantiomer; Lansoprazole

Indexed keywords

CLARITHROMYCIN; LANSOPRAZOLE; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DISPOSITION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ENANTIOSELECTIVITY; FEMALE; FIRST PASS EFFECT; GENOTYPE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ARYL HYDROCARBON HYDROXYLASES; CLARITHROMYCIN; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ENZYME INHIBITORS; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PROTON PUMPS; STEREOISOMERISM;

EID: 21844462524     PISSN: 08990042     EISSN: None     Source Type: Journal    
DOI: 10.1002/chir.20159     Document Type: Article

References (39)

1. Nagaya H, Satoh H, Maki Y. Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. J Pharmacol Exp Ther 1990;252:1289-1295.
2. Miwa H, Murai T, Sato K, Ohkura R, Yamada T, Nagahara A, Ohtaka K, Minowa T, Kurosawa A, Sato N. Comparison of the efficacy of 400 mg and 800 mg of clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection in a Japanese population. J Gastroenterol 2000;35:536-539.
3. Schwartz H, Krause R, Sahba B, Haber M, Weissfeld A, Rose P, Siepman N, Freston J. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. Am J Gastroenterol 1998;93:584-590.
4. Rodrigues AD, Roberts EM, Mulford DJ, Yao Y, Quellet D. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab Dispos 1997;25:623-630.
5. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara Jr EM, Hall SD. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and darithromycin. Clin Pharmacol Ther 1998:64:133-143.
6. Westphal JF. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 2000; 50:285-295.
7. Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A. Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 1996;277:805-816.
8. Katsuki H, Nakamura C, Arimori K, Fujiyama S, Nakano M, Katsuki H. Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects. Eur J Clin Pharmacol 1997;52: 391-396.
9. Pichard L, Curi-Pedrosa R, Bonds C, Jacqz-Aigrain E, Domerque J, Joyeux H, Cosme J, Guengerich FP. Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol 1995;47: 410-418.
10. Kim KA, Kim MJ, Park JY, Shon JH, Yoon YR, Lee SS, Liu KH, Chun JH, Hyun MH, Shin JG. Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. Drug Metab Dispos 2003; 31:1227-1234.
11. Sohn DR, Kwon JT, Kim HK, Ishizaki T. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status. Clin Pharmacol Ther 1997;61:574-582.
12. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 1999;13:27-36.
13. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Iselius L, Sjoqvist F. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-397.
14. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984;36:773-780.
15. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997;7:59-64.
16. Marinac JS, Balian JD, Foxworth JW, Willsie SK, Daus JC, Owen R, Flockhart DA. Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype. Clin Pharmacol Ther 1996;60:138-144.
17. Roh HK, Dahl ML, Tybring G, Yamada H, Cha YN, Bertilsson L. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 1996;6:547-551.
18. Kimura M, Ieiri I, Wada Y, Mamiya K, Urae A, Iimori E, Sakai T, Otsubo K, Higuchi S. Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy. Br J Clin Pharmacol 1999;47:115-119.
19. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985;38:402-408.
20. +)-ATPase activity in canine gastric microsomes and acid formation in isolated canine parietal cells. Biochem Pharmacol 1991;42:1875-1878.
21. Kim K, Shon J, Park J, Yoon Y, Kim M, Yun D, Kim M, Cha I, Hyun M, Shin J. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19. Clin Pharmacol Ther 2002;72:90-99.
22. Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K, Tateishi T, Suzuki T. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. Eur J Clin Pharmacol 2004;60:623-628.
23. Katsuki H, Hamada A, Nakamura C, Arimori K, Nakano M. Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes. Eur J Clin Pharmacol 2001;57: 709-715.
24. Rane A, Wilkinson GR, Shand DG. Prediction of hepatic extraction ratio from in vivo measurement of intrinsic clearance. J Pharmacol Exp Ther 1977;200:420-424.
25. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-598.
26. Miura M, Tada H, Suzuki T. Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction. J Chromatogr B 2004;804: 389-395.
27. Delhotal-Landes B, Cournot A, Vermerie N, Dellatolas F, Benoit M, Flouvat B. The effect of food and antacids on lansoprazole absorption and disposition. Eur J Drug Metab Pharmacokinet 1991;3:315-320.
28. Kivisto KT, Bookjans G, Fromm MF, Griese EU, Munzel P, Kroemer HK. Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br J Clin Pharmacol 1996;42:387-389.
29. Zhang QY, Dunbar D, Ostrowska A, Zeisloft S, Yang J, Kaminsky LS. Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 1999;27:804-809.
30. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM, Watkins PB. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994;4:247-259.
31. Yasui-Furukori N, Saito M, Uno T, Takahata T, Sugawara K, Tateishi T. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol 2004;44:1223-1229.
32. Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K, Tateishi T, Suzuki T. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. Br J Clin Pharmacol 2005; in press.
33. Wakasugi H, Yano I, Ito T, Hashida T, Futami T, Nohara R, Sasayama S, Inui K. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 1998;64: 123-128.
34. Rengelshausen J, Goggelmann C, Burhenne J, Riedel KD, Ludwig J, Weiss J, Mikus G, Walter-Sack I, Haefeli WE. Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin - clarithromycin interaction. Br J Clin Pharmacol 2003;56:32-38.
35. Tanaka H, Matsumoto K, Ueno K, Kodama M, Yoneda K, Katayama Y, Miyatake K. Effect of clarithromycin on steady-state digoxin concentrations. Ann Pharmacother 2003;37:178-181.
36. Kurata Y, Ieiri I, Kimura M, Morita T, Urae S, Urae A, Ohdo S, Ohtani H, Sawada Y, Higuchi S, Otsubo K. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002;72:209-219.
37. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 2001;364:551-557.
38. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001;69:158-168.
39. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2004;5: 181-202.